Results 41 to 50 of about 21,908,087 (195)

Somatic hypermutation of IGVH genes and aberrant somatic hypermutation in follicular lymphoma without BCL-2 gene rearrangement and expression

open access: yesHaematologica, 2008
Background Follicular lymphoma is characterized by the t(14;18) translocation resulting in constitutive expression of BCL-2 protein; however approximately 10–15% of follicular lymphomas do not express BCL-2 protein, and a small fraction of these cases ...
Éva Gagyi   +9 more
doaj   +1 more source

Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations

open access: yesNature Communications, 2019
Venetoclax is a first-in-class cancer therapy that interacts with the cellular apoptotic machinery promoting apoptosis. Treatment of patients suffering chronic lymphocytic leukaemia with this BCL-2 antagonist has revealed emergence of a drug-selected BCL-
R. Birkinshaw   +13 more
semanticscholar   +1 more source

Specific interactions of BCL-2 family proteins mediate sensitivity to BH3-mimetics in diffuse large B-cell lymphoma

open access: yesHaematologica, 2020
The BCL-2-specific inhibitor, ABT-199 (venetoclax) has exhibited remarkable clinical activity in nearly all cases of chronic lymphocytic leukemia. In contrast, responses are usually much less in diffuse large B-cell lymphoma (DLBCL), despite high level ...
Victoria M. Smith   +11 more
doaj   +1 more source

Silencing Bcl-2 Expression in Epithelial Cancer Cells Using “Smart” Particles

open access: yesJournal of Functional Biomaterials, 2014
Short interfering RNA (siRNA) targeted against anti-apoptotic Bcl-2 protein proved to knockdown its expression and trigger cancer cell death. We used degradable, pH-sensitive, comb-like [P(EAA-co-BMA)-b-PNASI-g-P(HMA-co-TMAEMA)] polymer to condense anti ...
Yen-Ling Lin   +4 more
doaj   +1 more source

Targeting the Bcl-2 Family in B Cell Lymphoma

open access: yesFrontiers in Oncology, 2019
Although lymphoma is a very heterogeneous group of biologically complex malignancies, tumor cells across all B cell lymphoma subtypes share a set of underlying traits that promote the development and sustain malignant B cells.
Clare M. Adams   +3 more
semanticscholar   +1 more source

Combined transfection of Bcl-2 siRNA and miR-15a oligonucleotides enhanced methotrexate-induced apoptosis in Raji cells

open access: yesCancer Biology & Medicine, 2013
Objective:B-cell lymphoma 2 (Bcl-2) is an important member of the Bcl-2 family of proteins that regulate the induction of apoptosis. This study aims to investigate whether Bcl-2 small interfering RNA (siRNA) combined with miR-15a oligonucleotides (ODN ...
Li Ding   +6 more
doaj   +1 more source

A novel Bcl-2 inhibitor, BM-1197, induces apoptosis in malignant lymphoma cells through the endogenous apoptotic pathway

open access: yesBMC Cancer, 2019
Bcl-2 family members play an important role in the development of malignant lymphoma and can induce drug resistance in anticancer treatment. The development of small molecules targeting Bcl-2 family proteins may be a new strategy for the treatment of ...
Yue-li Sun   +6 more
semanticscholar   +1 more source

BCL-2 as therapeutic target for hematological malignancies

open access: yesJournal of Hematology & Oncology, 2018
Disruption of the physiologic balance between cell proliferation and cell death is an important step of cancer development. Increased resistance to apoptosis is a key oncogenic mechanism in several hematological malignancies and, in many cases ...
G. Perini   +4 more
semanticscholar   +1 more source

Subcellular Localization and Dynamics of the Bcl-2 Family of Proteins

open access: yesFront. Cell Dev. Biol., 2018
Bcl-2 family proteins are recognized as major regulators of the mitochondrial pathway of apoptosis. They control the mitochondrial outer membrane permeabilization (MOMP) by directly localizing to this organelle.
N. Popgeorgiev, Lea Jabbour, G. Gillet
semanticscholar   +1 more source

Bcl-2 Inhibition to Overcome Resistance to Chemo- and Immunotherapy

open access: yesInternational Journal of Molecular Sciences, 2018
According to the World Health Organization (WHO), cancer is a leading cause of death worldwide. The identification of novel targets for cancer treatment is an area of intense work that has led Bcl-2 over-expression to be proposed as one of the hallmarks ...
M. García-Aranda   +2 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy